Researchers estimate three to four extra cases of ischemic optic neuropathy per 10,000 patients over 18 months, and say patients' underlying health may explain some or all of it.
Recap by typeshit. Full story at findarticles.
Dr. Nadolsky, an obesity medicine doctor, gives his take on a recent GLP-1 warning in a short clip. Tap through to see which warning he means.
14:36
A short look at the less discussed side effects of the experimental weight loss shot retatrutide, which is still in trials and not approved.
2:12
A short explainer on the experimental injection people call Reta, covering why it went viral and what is known so far about its safety.
A nationwide recall now covers a GLP-1 injectable. The full story names the affected medication and explains why it was pulled.
In a JAMA Network Open study of 3,615 adults, GLP-1 use was 20.5% among cancer survivors versus 26.5% in those without cancer, even though survivors carried more heart and kidney risk.
A cross-sectional study in Saudi Arabia looks at what adults know and think about antidiabetic medications taken for weight loss, and how many use them.
Loading…